Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Lava Therapeutics B.V.

Lava Therapeutics’ proprietary platform is focused on developing next generation ?d T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-oncology approach activates V?9Vd2 T cells upon binding to membrane-expressed tumor targets. Lava’s vision is to develop therapeutics for the curative treatment of cancer. Founded in 2016, Lava Therapeutics is advancing cutting-edge research originating from the group of Dr. Hans van der Vliet at the VU University Medical Center and Cancer Center Amsterdam. *


Period Start 2016-01-01 established
Products Industry gamma-delta T cell engager
  Industry 2 immunomodulatory cancer drug
Person Person Hurly, Stephen (Lava Therapeutics 202005 CEO formerly 201307 CEO of Burrill Securities LLC)
Region Region ’s-Hertogenbosch (den Bosch)
  Country Netherlands
  Street 225 Onderwijsboulevard
  City 5223 DE ’s-Hertogenbosch
  Tel +31-8-506-57344
    Address record changed: 2018-05-25
Basic data Employees n. a.
    * Document for �About Section�: Lava Therapeutics B.V.. (5/23/18). "Press Release: Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform. Biologics Expert Paul Parren Joins as Head of R&D". ’s Hertogenbosch.
Record changed: 2020-06-08


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Lava Therapeutics B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top